Sai Charan Vedula

Nephrologist

[Jen Bergeron @DrJennyBee]

Sharing my google spreadsheet of all the US Nephrology Fellowship Programs. It is a compilation of publicly available databases to show their size, transplant numbers, sub-subspecialities, and self-reported percentage of IMG/DO students the last 5 years.
https://t.co/1PzGl9Mg7l

[NDT @NDTsocial]

Kidney biopsy during pregnancy: indications, complications, results and therapeutic impact

https://t.co/LK6zBM7AUC

[Roger Rodby @NephRodby]

80 cases of hydralazine induced vasculitis! I remember the first one I saw 25 yr ago. Wasn't even on our radar. Now seems epidemic. How did this lousy - side effect laden - tid drug rise from the grave? Cardiologists? https://t.co/2pV8XvEWoG

[Amitabh Yaduvanshi MD, DM, FACC, FSCAI @IntervnCardio]

1/9
The 2026 ACC/AHA Dyslipidemia Guidelines are officially here!
Replacing the 2018 guidelines, these new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets.
Here are the most salient features you need to know. ����👇
#Cardiology #MedTwitter

[EJHF Editor-in-Chief @EJHFEiC]

The chloride paradigm shift in heart failure: From neglected ion to keystone of precision diuretic therapy

#EJHF @ESC_Journals

@HanCardiomd @GiuseppeGalati_ @AmrAbdin10

https://t.co/UeBjDmkIAW

[Dr. Hardik Patel 🩺💉 @hardik4u24]

Which drug does what to the nephron & heart?

This single graphic shows the differences:

🟥 RAASi — eGFR dip, MACE↓
🟧 ARNI — NT-proBNP↓
🟩 SGLT2i — proteinuria↓
🟦 ns-MRA — fibrosis↓
🟪 GLP-1 RA — HFH↓

🔗 https://t.co/ruDprocbLm 🆕

#CardioRenal #HFpEF #HFrEF #CKD

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines ca. 2024 from @journal_CHEST
#Nephpearls

👉 https://t.co/S7aWTb6s3q

[Dr. Hardik Patel 🩺💉 @hardik4u24]

📸 Integrated model of IgA Nephropathy pathogenesis with targeted therapies 🧬🦠🫘 @CKJsocial

🔗 https://t.co/tW1cRuz3SI 🆕

#IgAN #NephTwitter

[Dr. Hardik Patel 🩺💉 @hardik4u24]

💥Membranous Nephropathy: Expanding Antigen Map 🗺️

🔬Distinct biopsy clues & disease links redefine MN diagnosis

🔗https://t.co/PR3W6U5RE9 🆕

#NephTwitter #MN #Membranous #Nephropathy

[Dr. Hardik Patel 🩺💉 @hardik4u24]

🫃#Obesity drives CKD🫘 mostly indirectly (56–83%) via HTN, T2DM & atherosclerosis.

💉GLP-1 RAs hit every mediator: massive weight loss 📉+ BP/glucose control 📏+ direct kidney/cardio protection🫀

Game-changing for obese CKD patients ± DM
https://t.co/K7viCjNl0q
#CKD #GLP1

[Jasmine Sethi @JasmineNephro]

💊Drugs to prevent CKD progression

https://t.co/jdgpckPUJU

@NDTsocial @hjanders_hans

[Jasmine Sethi @JasmineNephro]

😬🫘Nephrotoxicity of chemotherapy agents

https://t.co/slfZTwWsR0

@NDTsocial @hjanders_hans

[Samir Nangia MD CPE ACC @SamirNangia]

What a fantastic night celebrating 20 years of Dallas Renal Group 🎉
We were proud to recognize staff with 5+ years of service—your care have been the driving force behind our success. 💙 #DRG20Years #TeamDRG #Gratitude @DallasRenal

[Rajiv Agarwal MD, MS @AgarwalRajivMD]

New analysis of the CONFIDENCE trial reveals that the combo of finerenone & empagliflozin is more effective than either drug alone in reducing UACR in Asian patients with CKD & type 2 diabetes. The combination was also well-tolerated. #ESDN2025

https://t.co/YjeAOK5saD

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Phase 3 clinical trials open in 2025 evaluating new treatments for IgA Nephropathy #IgAN from @goKDIGO

👉🏼 https://t.co/MFlu0Bb3oW

[AJKD @AJKDonline]

In The Literature by @thebeanqueen15 @RichardJJohns11:

Native American Ancestry and Susceptibility to Mesoamerican Nephropathy

https://t.co/pVbJSe2mWk (FREE)

[Anagha Shreyas @Anaghashreyas]

✨ #GlomSeries: Landmark Trials in Membranous Nephropathy ✨

📌 Foundations

•Ponticelli regimen (1980s–90s): Steroids + alkylators → improved renal survival
•CNIs (cyclosporine/tacrolimus): effective but relapse & nephrotoxicity issues

📌 Rituximab Era

•GEMRITUX (2017): Rituximab + supportive therapy ↓ anti-PLA2R, ↑ remission
•MENTOR (2019): Rituximab > Cyclosporine for sustained remission (60% vs 20%)
•STARMEN (2021): Cyclophosphamide/steroids > Tacrolimus→Rituximab sequential
•RI-CYCLO (2021): Rituximab vs Cyclophosphamide/steroids → similar efficacy
•Long-term data (2021): CYC/steroids vs Tacrolimus/steroids → outcome insights

📌 Novel & Ongoing (2020–25)
•Obinutuzumab: Rescue in rituximab-resistant MN
•PRIME (2025, Japan): Rituximab monotherapy vs placebo in idiopathic MN
•REBOOT (UCSF, 2025): Belimumab + Rituximab combo under study
•Felzartamab (anti-CD38): Phase II promising; PROMINENT Phase III (2025) vs Tacrolimus launched
•Other biologics (bortezomib, daratumumab) explored in refractory MN

📌 Big Picture
➡️ From alkylators → CNIs → Rituximab → Next-gen biologics (Obinutuzumab, Belimumab, Felzartamab)
➡️ Focus shifting from remission alone → long-term renal survival & antigen-targeted therapy

#NephTwitter #GlomSeries #FOAMed #Nephpearls

[Jasmine Sethi @JasmineNephro]

🫘❤️‍🩹Sequential Nephron blockade in diuretic resistance

https://t.co/JyML9X6tHe

@AJKDonline

[Jasmine Sethi @JasmineNephro]

❤️‍🩹Heart Failure drugs use according to CKD stage

https://t.co/JyML9X5VRG

@AJKDonline

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Management of the Hemodialysis Patient with Catheter-Related Bloodstream (CRBSI) Infection ca. 2019 @nephrogeek1 @MikeAllonK360
#Nephpearls

👉🏼 https://t.co/VTt32zsclp